DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on August 06, 2007
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anxiety Disorders

Intervention: Quetiapine (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Ricardo Ruiz, MD, Study Director, Affiliation: AstraZeneca

Overall contact:
AstraZeneca Clinical Study Information, Phone: 1-800-236-9933, Email: information.center@astrazeneca.com

Summary

The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.

Clinical Details

Official title: A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Generalised Anxiety Disorder

Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: The primary objective of this study is to evaluate the change in the Hamilton Rating Scale for Anxiety (HAM-A) total score, from randomisation to the end of the treatment (Day 64).

Secondary outcome: The secondary objectives are to evaluate the changes (e.g. in anxiety symptoms, health-related quality of life and remission rate) by questionnaires, from randomisation to the end of the treatment (Day 64).

Eligibility

Minimum age: 66 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female patients, 66 years or older, with a documented clinical diagnosis of GAD.

- Absence of current episode of major depression

Exclusion Criteria:

- The presence of dementia or other mental disorder than GAD,

- Serious suicidal risk, uncontrolled hypertension, substance or alcohol abuse,

- A current diagnosis of cancer or current or past diagnosis of stroke

Locations and Contacts

AstraZeneca Clinical Study Information, Phone: 1-800-236-9933, Email: information.center@astrazeneca.com

Research Site, Birmingham, Alabama, United States; Not yet recruiting

Research Site, San Diego, California, United States; Not yet recruiting

Research Site, Ft Myers, Florida, United States; Not yet recruiting

Research Site, Sarasota, Florida, United States; Recruiting

Research Site, Gainsville, Florida, United States; Not yet recruiting

Research Site, Praha 10, Czech Republic; Not yet recruiting

Research Site, Sosnowiec, Poland; Not yet recruiting

Research site, Moscow, Russian Federation; Recruiting

Research Site, KRAKOW, Poland; Recruiting

Research Site, Katowice, Poland; Not yet recruiting

Research Site, Skorzewo, Poland; Recruiting

Research Site, Nizhiy Novgorod, Russian Federation; Recruiting

Research Site, LESZNO, Poland; Recruiting

Research Site, Dnepropetrovsk, Ukraine; Not yet recruiting

Research Site, Saratov, Russian Federation; Recruiting

Research Site, Voronezh, Russian Federation; Recruiting

Research Site, St-Petersburg, Russian Federation; Recruiting

Research Site, Odessa, Ukraine; Recruiting

Research Site, Arkhangelsk, Russian Federation; Recruiting

Research Site, Roswell, Gabon; Not yet recruiting

Research Site, Praha 6, Czech Republic; Not yet recruiting

Research Site, Stavropol, Russian Federation; Recruiting

Research Site, BIALYSTOK, Poland; Recruiting

Research Site, Kiev, Ukraine; Recruiting

Research Site, Gorlice, Poland; Recruiting

Research Site, Vinnitsa, Ukraine; Recruiting

Research Site, Lipetsk, Russian Federation; Recruiting

Research Site, Brno, Czech Republic; Not yet recruiting

Research Site, Wroclaw, Poland; Recruiting

Research Site, Praha 2, Czech Republic; Not yet recruiting

Research Site, Litomerice, Czech Republic; Not yet recruiting

Research Site, Viljandi, Estonia; Recruiting

Research Site, Perm, Russian Federation; Not yet recruiting

Research Site, Tallinn, Estonia; Recruiting

Research Site, Glevakha, Ukraine; Recruiting

Research Site, Lugansk, Ukraine; Recruiting

Research Site, Dnipropetrovsk, Ukraine; Recruiting

Research Site, Torun, Poland; Recruiting

Research Site, Izhevsk, Russian Federation; Recruiting

Research Site, Tartu, Estonia; Recruiting

Research Site, Donetsk, Ukraine; Not yet recruiting

Research Site, Boston, Massachusetts, United States; Recruiting

Research Site, BROOKLYN, New York, United States; Not yet recruiting

Research Site, Avon Lake, Ohio, United States; Recruiting

Research Site, Eugene, Oregon, United States; Recruiting

Research Site, Jenkintown, Pennsylvania, United States; Not yet recruiting

Researach Site, Memphis, Tennessee, United States; Not yet recruiting

Research Site, Austin, Texas, United States; Recruiting

Research Site, Houston, Texas, United States; Not yet recruiting

Research Site, San Antonio, Texas, United States; Recruiting

Additional Information

AstraZeneca Clinical Trial Information – Outside US

Starting date: September 2006
Last updated: June 28, 2007

Page last updated: August 06, 2007

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009